These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38249320)

  • 21. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
    Pehrson AL; Cremers T; Bétry C; van der Hart MG; Jørgensen L; Madsen M; Haddjeri N; Ebert B; Sanchez C
    Eur Neuropsychopharmacol; 2013 Feb; 23(2):133-45. PubMed ID: 22612991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for cortical dopamine in the paradoxical calming effects of psychostimulants.
    Harris SS; Green SM; Kumar M; Urs NM
    Sci Rep; 2022 Feb; 12(1):3129. PubMed ID: 35210489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor.
    Engleman EA; Perry KW; Mayle DA; Wong DT
    Neuropsychopharmacology; 1995 Jul; 12(4):287-95. PubMed ID: 7576005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difference in the in vivo influence of serotonin1A autoreceptors on serotonin release in prefrontal cortex and dorsal hippocampus of the same rat treated with fluoxetine.
    Li XM; Perry KW; Wong DT
    Chin J Physiol; 1999 Jun; 42(2):53-9. PubMed ID: 10513599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.
    Berridge CW; Devilbiss DM; Andrzejewski ME; Arnsten AF; Kelley AE; Schmeichel B; Hamilton C; Spencer RC
    Biol Psychiatry; 2006 Nov; 60(10):1111-20. PubMed ID: 16806100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
    Childress A; Sottile R; Khanbijian S
    Expert Rev Neurother; 2023; 23(11):945-953. PubMed ID: 37846759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
    Golembiowska K; Kowalska M; Bymaster FP
    Synapse; 2012 May; 66(5):435-44. PubMed ID: 22213370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noradrenergic terminals are the primary source of α
    Devoto P; Flore G; Saba P; Scheggi S; Mulas G; Gambarana C; Spiga S; Gessa GL
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():97-103. PubMed ID: 30472147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study.
    Allers KA; Dremencov E; Ceci A; Flik G; Ferger B; Cremers TI; Ittrich C; Sommer B
    J Sex Med; 2010 May; 7(5):1757-67. PubMed ID: 20163532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
    Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
    Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.
    Robinson CL; Parker K; Kataria S; Downs E; Supra R; Kaye AD; Viswanath O; Urits I
    Health Psychol Res; 2022; 10(3):38360. PubMed ID: 36168642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
    Viggiano D; Ruocco LA; Arcieri S; Sadile AG
    Neural Plast; 2004; 11(1-2):133-49. PubMed ID: 15303310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression.
    Mathews TA; Fedele DE; Coppelli FM; Avila AM; Murphy DL; Andrews AM
    J Neurosci Methods; 2004 Dec; 140(1-2):169-81. PubMed ID: 15589347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
    Bymaster FP; Golembiowska K; Kowalska M; Choi YK; Tarazi FI
    Synapse; 2012 Jun; 66(6):522-32. PubMed ID: 22298359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex.
    Ago Y; Nakamura S; Baba A; Matsuda T
    Neuropsychopharmacology; 2005 Jan; 30(1):43-51. PubMed ID: 15383832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey.
    Kodama T; Kojima T; Honda Y; Hosokawa T; Tsutsui KI; Watanabe M
    J Neurosci; 2017 Mar; 37(9):2387-2394. PubMed ID: 28154152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.
    Edinoff AN; Akuly HA; Wagner JH; Boudreaux MA; Kaplan LA; Yusuf S; Neuchat EE; Cornett EM; Boyer AG; Kaye AM; Kaye AD
    Front Psychiatry; 2021; 12():789982. PubMed ID: 34975586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple reuptake inhibition of serotonin, norepinephrine, and dopamine increases the tonic activation of α
    Jiang JL; El Mansari M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Dec; 103():109987. PubMed ID: 32474007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex.
    Huang M; Ichiwaka J; Li Z; Dai J; Meltzer HY
    Psychopharmacology (Berl); 2006 Apr; 185(3):274-81. PubMed ID: 16521036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
    Nasser A; Gomeni R; Wang Z; Kosheleff AR; Xie L; Adeojo LW; Schwabe S
    J Clin Pharmacol; 2021 Dec; 61(12):1626-1637. PubMed ID: 34269426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.